{"id":256,"date":"2011-04-29T16:22:33","date_gmt":"2011-04-29T20:22:33","guid":{"rendered":"http:\/\/blogstemp3.wpengine.com\/?p=256"},"modified":"2011-04-29T16:22:33","modified_gmt":"2011-04-29T20:22:33","slug":"the-treatment-of-chronic-hepatitis-c-do-we-finally-have-the-answer","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/the-treatment-of-chronic-hepatitis-c-do-we-finally-have-the-answer\/2011\/04\/29\/","title":{"rendered":"Treating chronic hepatitis C: Do we finally have the answer?"},"content":{"rendered":"<p>Although the treatment of chronic hepatitis C virus infection\u00a0has come a long way,\u00a0I have been \u00a0frustrated that\u00a0less than half of\u00a0patients are cured with current interferon\/ribavirin based therapy. That is why I have been closely watching the data related to the use of protease inhibitors such as telaprevir and boceprevir.<\/p>\n<p>Now that the data demonstrate the remarkable effectiveness of these agents, gastroenterologists will have to consider how and when they will be used, what changes in monitoring will be necessary, and whether infectious disease doctors will take over this treatment (<a href=\"http:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/hepatitis-c-week-is-upon-us\/2011\/04\/28\">http:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/hepatitis-c-week-is-upon-us\/2011\/04\/28<\/a>).<\/p>\n<p>So I am asking you:<br \/>\nWill you use these agents as soon as they become available?<br \/>\nAre you comfortable using a protease inhibitor along with IF\/ribavirin?<br \/>\nHow will this alter your monitoring?<br \/>\nWhat are your thoughts about ID specialists managing these patients?<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Although the treatment of chronic hepatitis C virus infection\u00a0has come a long way,\u00a0I have been \u00a0frustrated that\u00a0less than half of\u00a0patients are cured with current interferon\/ribavirin based therapy. That is why I have been closely watching the data related to the use of protease inhibitors such as telaprevir and boceprevir. Now that the data demonstrate the [&hellip;]<\/p>\n","protected":false},"author":28,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[22,39,55],"class_list":["post-256","post","type-post","status-publish","format-standard","hentry","category-hepatology","tag-boceprevir","tag-hepatitis","tag-telaprevir"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/posts\/256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/comments?post=256"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/posts\/256\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/media?parent=256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/categories?post=256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/gastroenterology\/index.php\/wp-json\/wp\/v2\/tags?post=256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}